Additionally, serum IP10, and MCP-1 levels were higher in the HCC group 12 weeks after therapy completion, and levels of distinct sets of miRNAs correlated with levels of IP10, MCP-1, and select peripheral blood mononuclear cell (PBMC) mRNA levels at these time points. The gene discussed is CXCL10; the disease is hepatocellular carcinoma.